Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Knight Therapeutics invests up to $125m in Latin America-focused Moksha8

    Knight Therapeutics invests up to $125m in Latin America-focused Moksha8

    Boehringer Ingelheim and IBM Canada Announce First of its Kind Collaboration to Integrate Blockchain Technology into Clinical Trials

    Boehringer Ingelheim and IBM Canada Announce First of its Kind Collaboration to Integrate Blockchain Technology into Clinical Trials

    AbbVie and Teneobio Announce a Strategic Transaction to Develop a New Treatment for Multiple Myeloma

    AbbVie and Teneobio Announce a Strategic Transaction to Develop a New Treatment for Multiple Myeloma

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EC Approves ADCETRIS with AVD, the First New Treatment in Decades for Adults with Previously Untreated CD30+ Stage IV Hodgkin Lymphoma

    EC Approves ADCETRIS with AVD, the First New Treatment in Decades for Adults with Previously Untreated CD30+ Stage IV Hodgkin Lymphoma

    EC Approves Bristol-Myers Squibb’s Sprycel in Combination with Chemotherapy for Treatment of Pediatric Patients

    EC Approves Bristol-Myers Squibb’s Sprycel in Combination with Chemotherapy for Treatment of Pediatric Patients

    Samsung Bioepis and C-Bridge Capital to Develop and Commercialize Next-Generation Biosimilars in China

    Samsung Bioepis and C-Bridge Capital to Develop and Commercialize Next-Generation Biosimilars in China

    US FDA grants Breakthrough Therapy Designation for potential next-generation RSV medicine MEDI8897

    US FDA grants Breakthrough Therapy Designation for potential next-generation RSV medicine MEDI8897

    Solentim and ATUM announce technology collaboration to enable rapid, high expression, stable cell line development

    Solentim and ATUM announce technology collaboration to enable rapid, high expression, stable cell line development

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Knight Therapeutics invests up to $125m in Latin America-focused Moksha8

    Knight Therapeutics invests up to $125m in Latin America-focused Moksha8

    Boehringer Ingelheim and IBM Canada Announce First of its Kind Collaboration to Integrate Blockchain Technology into Clinical Trials

    Boehringer Ingelheim and IBM Canada Announce First of its Kind Collaboration to Integrate Blockchain Technology into Clinical Trials

    AbbVie and Teneobio Announce a Strategic Transaction to Develop a New Treatment for Multiple Myeloma

    AbbVie and Teneobio Announce a Strategic Transaction to Develop a New Treatment for Multiple Myeloma

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EC Approves ADCETRIS with AVD, the First New Treatment in Decades for Adults with Previously Untreated CD30+ Stage IV Hodgkin Lymphoma

    EC Approves ADCETRIS with AVD, the First New Treatment in Decades for Adults with Previously Untreated CD30+ Stage IV Hodgkin Lymphoma

    EC Approves Bristol-Myers Squibb’s Sprycel in Combination with Chemotherapy for Treatment of Pediatric Patients

    EC Approves Bristol-Myers Squibb’s Sprycel in Combination with Chemotherapy for Treatment of Pediatric Patients

    Samsung Bioepis and C-Bridge Capital to Develop and Commercialize Next-Generation Biosimilars in China

    Samsung Bioepis and C-Bridge Capital to Develop and Commercialize Next-Generation Biosimilars in China

    US FDA grants Breakthrough Therapy Designation for potential next-generation RSV medicine MEDI8897

    US FDA grants Breakthrough Therapy Designation for potential next-generation RSV medicine MEDI8897

    Solentim and ATUM announce technology collaboration to enable rapid, high expression, stable cell line development

    Solentim and ATUM announce technology collaboration to enable rapid, high expression, stable cell line development

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development

FDA Approves First Drug Using the Recombinant Factor C Assay for Endotoxin Testing

Content Team by Content Team
12th November 2018
in Drug Development, FDA Approvals
FDA Approves First Drug Using the Recombinant Factor C Assay for Endotoxin Testing

Lonza announced that the recombinant Factor C Assay has been used for endotoxin testing of Eli Lilly’s Emgality™ , the first drug approved by the U.S. FDA to have been released using this method instead of traditional Limulus Amebocyte Lysate (LAL) – based methods. Emgality™ is a monoclonal antibody drug treatment for the prevention of migraine in adults.

In 2003 Lonza launched the PyroGene™ recombinant Factor C Assay, the first endotoxin testing method to utilize a recombinant form of Factor C, the first component in the horseshoe-crab clotting cascade activated by the presence of endotoxins. As an animal-free method, the PyroGene™ Assay offers a more sustainable alternative to LAL-based tests that use the lysate obtained from horseshoe crab blood as their main ingredient.

“The recent FDA approval of Emgality™ marks a significant breakthrough in establishing the recombinant Factor C Assay as the non-animal method of choice for the identification of contaminating endotoxins in drug products,” said Lakiya Wimbish, Product Manager for Lonza’s PyroGene™ Recombinant Factor C Assay. “This development serves as an official confirmation that the recombinant Factor C method can be as accurate, sensitive and specific as LAL-based methods, while helping to secure the supply of natural resources.”

Allen Burgenson, Lonza’s Global Subject Matter Expert for Endotoxin Testing Solutions, said, “Lonza is the commercial innovator in bringing recombinant technology for endotoxin testing to market. This milestone accomplishment in advancing rFC technology will help to ensure the sustainability of the world’s horseshoe crab species. The three species of horseshoe crab found in Asia (Carcinoscorpius rotundicauda, Tachypleus tridentatus and Tachypleus gigas) are in serious decline due to overfishing, habitat loss and their use as a regional food. As these species become depleted due to a lack of regulatory oversight, countries such as China that use them to prepare Tachypleus Amebocyte Lysate (TAL) will look to the North American species, Limulus polyphemus, to fulfill their ever increasing needs in order to release non-pyrogenic pharmaceutical products to the market. Use of recombinant products, such as recombinant Factor C for endotoxin detection will greatly reduce the pressure on these species.”

More information about Lonza’s PyroGene™ Recombinant Factor C Assay is available on the Lonza website: www.lonza.com/pyrogene

About Lonza
Lonza is one of the world’s leading and most-trusted suppliers to the pharmaceutical, biotech and specialty ingredients markets. As an integrated solutions provider, Lonza is boosting its value creation along and beyond the healthcare continuum with a strong focus on patient healthcare, consumer preventive healthcare and consumer’s healthy environment. Lonza harnesses science and technology to create products that support safer and healthier living and that enhance the overall quality of life. With the recent Capsugel acquisition, Lonza now offers products and services from the custom development and manufacturing of active pharmaceutical ingredients to innovative dosage forms for the pharma and consumer health and nutrition industries.

Benefiting from its regulatory expertise, Lonza is able to transfer its know-how from pharma to hygiene and fast-moving consumer goods all the way to coatings and composites and the preservation and protection of agricultural goods and other natural resources.

Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with more than 100 sites and offices and approximately 14,500 full-time employees worldwide. The company generated sales of CHF 5.1 billion in 2017 with a CORE EBITDA of CHF 1.3 billion. Further information can be found at www.lonza.com

Previous Post

Almac Clinical Services Wins Excellence Awards at 2018 Cold Chain Global Forum

Next Post

SIRIO Pharma opens multimillion gummy production plant at new high-tech nutraceutical facility in Ma’anshan, China

Related Posts

Knight Therapeutics invests up to $125m in Latin America-focused Moksha8
Drug Development

Knight Therapeutics invests up to $125m in Latin America-focused Moksha8

21st February 2019
Boehringer Ingelheim and IBM Canada Announce First of its Kind Collaboration to Integrate Blockchain Technology into Clinical Trials
Clinical Trials

Boehringer Ingelheim and IBM Canada Announce First of its Kind Collaboration to Integrate Blockchain Technology into Clinical Trials

13th February 2019
AbbVie and Teneobio Announce a Strategic Transaction to Develop a New Treatment for Multiple Myeloma
Drug Development

AbbVie and Teneobio Announce a Strategic Transaction to Develop a New Treatment for Multiple Myeloma

13th February 2019
U.S. FDA Approves DARZALEX Split-Dosing Regimen
FDA Approvals

U.S. FDA Approves DARZALEX Split-Dosing Regimen

13th February 2019
EC Approves ADCETRIS with AVD, the First New Treatment in Decades for Adults with Previously Untreated CD30+ Stage IV Hodgkin Lymphoma
FDA Approvals

EC Approves ADCETRIS with AVD, the First New Treatment in Decades for Adults with Previously Untreated CD30+ Stage IV Hodgkin Lymphoma

12th February 2019
EC Approves Bristol-Myers Squibb’s Sprycel in Combination with Chemotherapy for Treatment of Pediatric Patients
FDA Approvals

EC Approves Bristol-Myers Squibb’s Sprycel in Combination with Chemotherapy for Treatment of Pediatric Patients

12th February 2019
Next Post

SIRIO Pharma opens multimillion gummy production plant at new high-tech nutraceutical facility in Ma’anshan, China

Latest News

Knight Therapeutics invests up to $125m in Latin America-focused Moksha8
Drug Development

Knight Therapeutics invests up to $125m in Latin America-focused Moksha8

21st February 2019
Medicine’s just the beginning: eyeforpharma Barcelona 2019 is at record attendance this is going to be the greatest one yet
Manufacturing

Medicine’s just the beginning: eyeforpharma Barcelona 2019 is at record attendance this is going to be the greatest one yet

20th February 2019
Boehringer Ingelheim and IBM Canada Announce First of its Kind Collaboration to Integrate Blockchain Technology into Clinical Trials
Clinical Trials

Boehringer Ingelheim and IBM Canada Announce First of its Kind Collaboration to Integrate Blockchain Technology into Clinical Trials

13th February 2019
WuXi Biologics and Amicus Sign Exclusive Manufacturing Partnership
Manufacturing

WuXi Biologics and Amicus Sign Exclusive Manufacturing Partnership

13th February 2019
AbbVie and Teneobio Announce a Strategic Transaction to Develop a New Treatment for Multiple Myeloma
Drug Development

AbbVie and Teneobio Announce a Strategic Transaction to Develop a New Treatment for Multiple Myeloma

13th February 2019
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Market Moves OLD
  • Manufacturing
  • News
  • Events & Conferences

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Download Media Pack

Close

x
No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In